Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03008070 · ClinicalTrials.gov registry record · Phase 2
Phase 2b Study in NASH to Assess IVA337
A Phase 2 study of Non-alcoholic Steatohepatitis (NASH), sponsored by Inventiva Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 247
- Enrollment target
- 20
- Study locations
NCT03008070 is a Phase 2 study of Non-alcoholic Steatohepatitis (NASH) that has completed, run by Inventiva Pharma. The registered enrollment target is 247 participants, above the 141-participant average among 8 other Non-alcoholic Steatohepatitis (NASH) trials with a reported enrollment target (75% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT03008070, a Phase 2 study of Non-alcoholic Steatohepatitis (NASH), has completed, sponsored by Inventiva Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 247 participants
- Enrollment target
- 20
- Study locations
Study Summary
Non-alcoholic steatohepatitis, abbreviated as NASH, is a chronic liver disease that may progress to cirrhosis. The disease is mostly associated with obesity and type 2 diabetes mellitus, or insulin resistance and is very common. However, Treatment of NASH is a significant unmet clinical need. IVA337 (lanifibranor) is a next generation pan-PPAR (peroxisome proliferator-activated receptors) agonist addressing the pathophysiology of NASH : metabolic, inflammatory and fibrotic. The purpose of this research is to evaluate the efficacy and the safety of two doses of IVA337 (800mg, 1200 mg) per day for 24 weeks versus placebo in adult NASH patients with liver steatosis and moderate to severe necroinflammation without cirrhosis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG IVA337
Study Locations (20)
Other
- Flinders Medical Centre Department of Hepatology - Bedford Park
- Monash Medical Centre - Clayton
- Lyell McEwin Hospital & The University of Adelaide - Elizabeth Vale
- Royal Brisbane and Women's Hospital - Herston
- Fiona Stanley Hospital - Murdoch
- Medical University Vienna - Vienna
California
- ACTRI - La Jolla
- National Research Institute - Los Angeles
Florida
- Palmetto Research, LLC - Hialeah
- Florida Digestive Health Specialists, LLP - Lakewood Rch
North Carolina
- Duke University Medical Center - Durham
- Carolina's Center for Liver Disease/CHG - Huntersville
Texas
- The Texas Liver Institute - San Antonio
- Digestive Health Research, LLC - San Antonio
Virginia
- University of Virginia Health System - Charlottesville
- Virginia Commonwealth University - Richmond
Alabama
- North Alabama GI Research Center - Madison
Massachusetts
- Northeast GI Research Division - Concord
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 247 participants |
| Start Date | 2017-02-07 |
| Est. Completion | 2020-03-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03008070
The ClinicalTrials.gov registry entry for NCT03008070 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 247 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 141-participant average among 8 other Non-alcoholic Steatohepatitis (NASH) trials with a reported enrollment target (75% higher). The listed sponsor is Inventiva Pharma, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-alcoholic Steatohepatitis (NASH) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03008070 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT03008070 about?
NCT03008070 is a clinical study titled "Phase 2b Study in NASH to Assess IVA337". Non-alcoholic steatohepatitis, abbreviated as NASH, is a chronic liver disease that may progress to cirrhosis. The disease is mostly associated with obesity and type 2 diabetes mellitus, or insulin resistance and is very common. However, Treatment of NASH is a significant unmet clinical need. IVA33...
What is the current status of trial NCT03008070?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 247 participants. The study started on 2017-02-07. Estimated completion is 2020-03-16.
What conditions does trial NCT03008070 study?
This clinical trial studies the following conditions: Non-alcoholic Steatohepatitis (NASH).
What interventions are being tested in trial NCT03008070?
The interventions under investigation include: Placebo (DRUG), IVA337 (DRUG).
Who is sponsoring clinical trial NCT03008070?
This trial is sponsored by Inventiva Pharma, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03008070 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Massachusetts, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-alcoholic Steatohepatitis (NASH)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis
COMPLETED · Phase 2
-
IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)
COMPLETED · Phase 2
-
Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3
COMPLETED · Phase 2
-
A Phase 2b Study of Icosabutate in Fatty Liver Disease
COMPLETED · Phase 2
-
Non-alcoholic Fatty Liver Disease Parametric PET (FLiPP) Study
ACTIVE NOT RECRUITING
-
A Physiologic Analysis of Endoscopic Sleeve Gastroplasty (ESG)
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.